Benefits
Satiety enhancement via galactomannan fiber
Galactomannans (≥20% of Csat+) form a viscous mass in the gastrointestinal tract, contributing to enhanced satiety by physically occupying volume and delaying gastric emptying. The fiber-driven satiety mechanism is distinct from hormonal appetite suppression — addresses fullness and reduces subsequent food intake through gastric distension signaling.
Insulin sensitivity via inositols
Inositols (≥5% of Csat+) improve insulin-receptor sensitivity and promote glucose uptake through the GLUT4 transporter into muscle and adipose cells. Same mechanism as standalone inositol supplementation for metabolic syndrome and PCOS — Csat+ delivers a smaller inositol dose alongside the other carob bioactives as part of a multi-component approach.
α-Amylase inhibition for glucose control
The polyphenol fraction (including gallic acid) is associated with pancreatic and salivary α-amylase inhibition — slowing the breakdown of dietary starches into absorbable sugars. This reduces post-meal glucose spikes. Mechanism similar to acarbose (the diabetes drug) but milder.
Cholesterol and triglyceride reduction
Galactomannan fiber from carob has documented effects on lipid profile — reducing total cholesterol, LDL cholesterol, and triglycerides. Mechanism involves bile acid binding (forcing the liver to use more cholesterol to synthesize new bile acids) and reduced cholesterol absorption from the gut.
Prebiotic fiber and oligofructose content
Csat+ provides prebiotic fibers (oligofructoses) that support beneficial gut microbiome composition. The improved lipid metabolism and weight management effects may be partly mediated through gut microbiome shifts — connecting the gut-metabolic axis to the ingredient's overall satiety and weight outcomes.
Antioxidant support via gallic acid
Gallic acid (≥0.1% of Csat+) is the main polyphenol in carob pod and reduces generalized oxidative stress in situations such as metabolic syndrome. Oxidative stress contributes to insulin resistance and adverse metabolic outcomes — antioxidant activity supports the broader metabolic health positioning beyond satiety effects alone.
Industry recognition — NutraIngredients Awards finalist
Csat+ was recognized as a finalist for Ingredient of the Year for Weight Management at the NutraIngredients Awards — independent industry validation beyond manufacturer marketing. Patent protection (international patent WO 2019/068466 A1) covers the proprietary extraction process that yields the standardized Sliminoids® complex. Distinguishes Csat+ from generic carob fiber products that lack standardization and clinical positioning.
Mechanism of action
Viscous fiber gastric distension
Galactomannan from carob seed endosperm forms a viscous gel in the stomach, expanding to occupy volume and signaling fullness via mechanoreceptors in the gastric wall. The gel also slows gastric emptying — sustaining satiety over extended periods. Same mechanism as glucomannan from konjac root, another well-established satiety fiber.
IPG second-messenger insulin signaling
Inositols from carob support inositol phosphoglycan (IPG) second-messenger pathways that mediate insulin receptor signaling. Improved IPG signaling means cells respond better to circulating insulin, supporting glucose uptake and metabolic health. The same mechanism established for myo-inositol in PCOS and metabolic syndrome.
α-Amylase enzymatic inhibition
Carob polyphenols inhibit both pancreatic and salivary α-amylase — the enzymes responsible for starch breakdown into absorbable monosaccharides. Slowing this conversion reduces post-prandial glucose spikes. The same enzyme target as the diabetes drug acarbose, though Csat+'s effect is milder.
Bile acid binding and cholesterol metabolism
Soluble fiber from carob binds bile acids in the gut, preventing their reabsorption and forcing the liver to synthesize new bile acids using circulating cholesterol. This 'cholesterol drain' lowers serum cholesterol levels — the same mechanism as cholestyramine and other bile acid sequestrant medications.
Clinical trials
Preclinical research in vivo (mice models) characterizing Csat+'s satiety, glucose, and lipid effects. Provides mechanistic foundation supporting the three synergistic pathways (galactomannan satiety, inositol insulin sensitization, polyphenol α-amylase inhibition). Available consumer organoleptic testing supports practical use cases.
Not applicable — in vivo animal model studies.
Csat+ demonstrated satiating effects, glucose-balancing activity, and lipid metabolism improvement in vivo. Established the 'inside-out' synergistic mechanism that positions Csat+ for weight management alongside lifestyle modifications. Provided the rationale for the NutraIngredients Awards 2020 Weight Management finalist recognition and the international patent (WO 2019/068466 A1).
Beyond Csat+-specific trials, each bioactive class within Csat+ has independent human clinical trial evidence in related contexts: galactomannan fiber for satiety and lipid effects, inositol for insulin sensitivity and PCOS, and gallic acid for antioxidant and metabolic effects.
Various — clinical trials of individual bioactive classes across different supplementation contexts.
Galactomannan fiber consistently produces satiety and lipid-lowering effects across trials. Myo-inositol at 2-4 g/day improves insulin sensitivity and metabolic markers, particularly in PCOS. Polyphenols support glucose management via α-amylase inhibition. The combination in Csat+ targets multiple pathways simultaneously, potentially producing additive effects beyond single-component supplementation.